Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01792518 · ClinicalTrials.gov registry record · Phase 3
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 360
- Enrollment target
NCT01792518 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 360 participants.
The verdict
NCT01792518, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 360 participants
- Enrollment target
Study Summary
Evaluate linagliptin in terms of glycemic control as defined by HbA1c after 24 weeks of treatment and in terms of renal efficacy as defined by changes in albuminuria (UACR) after 24 weeks of treatment.
Interventions
- DRUG Placebo
- DRUG Linagliptin 5mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2013-02 |
| Est. Completion | 2015-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01792518
The ClinicalTrials.gov registry entry for NCT01792518 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01792518 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01792518 about?
NCT01792518 is a clinical study titled "MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin". Evaluate linagliptin in terms of glycemic control as defined by HbA1c after 24 weeks of treatment and in terms of renal efficacy as defined by changes in albuminuria (UACR) after 24 weeks of treatment.
What is the current status of trial NCT01792518?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 360 participants. The study started on 2013-02. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01792518?
The interventions under investigation include: Placebo (DRUG), Linagliptin 5mg (DRUG).
Who is sponsoring clinical trial NCT01792518?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.